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Fatigue is one of the most pervasive symptoms of multiple sclerosis (MS), and has engen-
dered hundreds of investigations on the topic. While there is a growing literature using
various methods to study fatigue, a unified theory of fatigue in MS is yet to emerge.
In the current review, we synthesize findings from neuroimaging, pharmacological, neu-
ropsychological, and immunological studies of fatigue in MS, which point to a specific
hypothesis of fatigue in MS: the dopamine imbalance hypothesis. The communication
between the striatum and prefrontal cortex is reliant on dopamine, a modulatory neu-
rotransmitter. Neuroimaging findings suggest that fatigue results from the disruption of
communication between these regions. Supporting the dopamine imbalance hypothesis,
structural and functional neuroimaging studies show abnormalities in the frontal and striatal
regions that are heavily innervated by dopamine neurons. Further, dopaminergic psychos-
timulant medication has been shown to alleviate fatigue in individuals with traumatic brain
injury, chronic fatigue syndrome, and in cancer patients, also indicating that dopamine
might play an important role in fatigue perception. This paper reviews the structural and
functional neuroimaging evidence as well as pharmacological studies that suggest that
dopamine plays a critical role in the phenomenon of fatigue.We conclude with how specific
aspects of the dopamine imbalance hypothesis can be tested in future research.
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INTRODUCTION
Fatigue is a common symptom in multiple sclerosis (MS), with up
to 90% of individuals with MS reporting fatigue (1). Moreover,
more than half of individuals with MS report fatigue to be their
worst symptom (2). For this reason, the topic of fatigue in MS has
generated a great deal of research in the domains of neuropsychol-
ogy, neuroscience, and pharmacology. Other clinical populations
also report fatigue including: 80% of individuals with traumatic
brain injury (TBI) (3), 56% of individuals with Parkinson’s Dis-
ease (PD) (4), 99% of cancer patients (5), 88% of individuals with
human immunodeficiency virus (88%) (6), as well as individu-
als with chronic fatigue syndrome (CFS) who experience fatigue
for more than 6 months for no known psychiatric or neurological
reasons (7).
Fatigue is characterized by a lack of energy, feelings of exhaus-
tion that are unaided by sleep, and the perception that one is
unable to perform mental and physical activities (8). Although
fatigue has been studied extensively, in part because it affects such
a wide range of clinical populations, there has been no unifying
framework within which to understand fatigue. In this review, we
propose such a framework, with the aim of providing structure for
this developing field of study.
We propose that fatigue arises due to a dopamine imbalance
within the central nervous system (CNS). One of the ultimate
goals of this review is to investigate the evidence that supports the
dopamine imbalance hypothesis by examining studies showing
structural and functional abnormalities in areas enervated by
dopamine and clinical trials showing alleviation of fatigue after
dopamine medication.
The current review examines the evidence in support of the
dopamine imbalance hypothesis by focusing on central fatigue,
which can be experienced as both physical and mental in nature.
Further, the current review builds upon a previous framework of
fatigue proposed by Chaudhuri and Behan (9), which suggests that
central fatigue might arise due to the “failure of the non-motor
functions of the basal ganglia” [(9), p. 40]. This hypothesis was
developed based on evidence from both animal and clinical stud-
ies, which showed the effects of basal ganglia damage to be similar
to the symptoms of central fatigue. The authors emphasized sub-
cortical pallido–thalamo-cortical interactions and urged to clarify
the influence of dopamine and serotonin on fatigue, since these
neurotransmitters effect the activation of the pallido–thalamo-
cortical loop. In the current review, we suggest a more precise
mechanism based on recent studies that fatigue might develop as
a result of a dopamine imbalance.
DOPAMINE: A BRIEF REVIEW
Dopamine is a modulatory neurotransmitter that is termed a cate-
cholamine due to its chemical composition. Dopamine is the most
common catecholamine in the CNS (10, 11) and is a precursor
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to the two other catecholamines, norepinephrine and epineph-
rine. In the CNS, dopamine is synthesized in two subcortical
brain regions, specifically, the substantia nigra pars compact (SNc)
and the ventral tegmental area (VTA) (10, 12–14). Dopaminergic
neurons project from the SNc and VTA to various cortical areas
and thus can be segregated onto several dopaminergic pathways:
(1) the nigrostriatal pathway, which links the SNc with the stria-
tum, and (2) the mesocorticolimbic pathway, which starts at the
VTA and projects to the striatum, limbic areas, and the prefrontal
cortex (PFC) (10, 13, 15, 16). Finally, dopamine from a third
pathway is synthesized in the hypothalamus and projects to the
pituitary gland, where it is involved in the inhibition of prolactin
release, a hormone that is important in immune system regula-
tion1 (10) (Figure 1). Catecholamines also play an important role
in the modulation of the immune system, with dopamine being
synthesized and released by immune cells (17, 18).
Dopamine receptors (DRs) can be found in both the CNS and
in the immune system. There are five types of DRs (D1, D2, D3, D4,
and D5), subdivided into two groups: D1-like and D2-like. The D1
and D5 receptors belong to the D1-like group, while the rest of the
DRs belong to the D2-like group of receptors (10, 13). These recep-
tors have different distribution densities in the CNS, depending on
the brain region. For example, more D1-like receptors are located
in the PFC, while more D2-like receptors are found in the striatum.
Therefore, different medications have a somewhat specific affinity
for DRs and that way can have a greater effect on a specific brain
region (e.g., a medication targeting D1 may have more influence
on the PFC and its function than on the striatum) (19).
1Note that there are actually four pathways: (1) nigrostriatal, (2) mesolimbic,
(3) mesocortical, and (4) hypothalamic (tuberoinfundibular). However, in human
research, whether it is pharmacological or neuroimaging, it is not possible to specif-
ically delineate the pathways, hence, here, we collapse the second and the third
pathways, referring to them as the mesocorticolimbic pathway.
FIGURE 1 | A representation of dopaminergic projections throughout
the brain. Adapted from Dalley and Roiser (14).
Dopamine has been known to play an important role in motor
function. However, evidence from several past decades show that
dopamine also plays a significant role in motivation and cogni-
tion. Specifically, dopamine has been shown to be involved in
learning of action–outcome associations (20–22). In addition,
dopamine has been shown to be involved in effortful behavior:
the depletion of dopamine from the striatum or the adminis-
tration of dopamine antagonists has been shown to result in
the cessation of effortful reward-seeking behavior. That is, ani-
mals that learned to exert effort (e.g., climb a barrier or press
a lever several times) for a larger food reward, start to prefer
a smaller reward that can be obtained without effort exertion
(23, 24). PFC dopamine has been shown to play an important
role in working memory (25, 26). Further, increased amount
of dopamine release in the striatum and the PFC has been
shown to be associated with cognitive flexibility [see Ref. (27)
for review].
THE EFFECTS OF DOPAMINE ON FATIGUE IN THE CENTRAL
NERVOUS SYSTEM
SUPPORT FROM STRUCTURAL NEUROIMAGING
Dopamine imbalance can be caused by changes in brain structure,
particularly when structures critical for dopaminergic projections
are damaged. Recent structural neuroimaging studies implicate
regions of the mesocorticolimbic pathway with the fatigue expe-
rienced by several clinical populations, including those with MS.
Structural impairments in the VMPFC and the striatum have been
observed in fatigued individuals, suggesting a role for dopamine
in fatigue (28). Pardini et al. (29) found that reduced white
matter integrity in the VMPFC, a region that receives dopamin-
ergic projections, was associated with increased fatigue in MS.
In another investigation, Pardini et al. (30) assessed fatigue in
individuals with TBI, finding that persons with damage localized
to the VMPFC had higher levels of fatigue relative to persons
with damage localized to the dorsolateral PFC or other areas of
the cortex. Genova et al. (31) also showed that individuals with
MS who have high fatigue have increased white matter pathol-
ogy in the internal capsule, which links the striatum with the
PFC (32).
Further evidence for the involvement of the mesocorticolimbic
regions comes from stroke research: Tang et al. (33, 34) reported
that striatal infarcts are associated with post-stroke fatigue. Addi-
tionally, magnetic resonance spectroscopy findings showed lower
levels of choline concentration and N -acetylcholine/creatine ratio
(indicative of decreased neuronal integrity) in the striatum in
patients with CFS and MS, respectively (9, 35).
SUPPORT FROM FUNCTIONAL NEUROIMAGING
Several functional neuroimaging studies also point to the involve-
ment of mesocorticolimbic pathway in individuals with neurolog-
ical damage who report fatigue. One of the earliest functional
neuroimaging studies that implicated dopaminergic regions in
fatigue used positron emission tomography (PET) to assess differ-
ences in brain activity at rest (i.e., without task) in individuals with
MS (36). MS individuals, who scored high on the Fatigue Severity
Scale (FSS) (37) exhibited reduced regional synaptic activity. That
is, they exhibited lower levels of glucose metabolism in the PFC
and in the striatum compared to individuals with MS who did not
report fatigue (36).
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Functional magnetic resonance imaging (fMRI) studies fur-
ther support the dopamine imbalance hypothesis. Esposito and
colleagues (38) examined the influence of fatigue in healthy indi-
viduals on resting-state network activity, i.e., task-independent
activation of brain networks. Healthy individuals were scanned
both at rest and while performing the n-back task at the begin-
ning and at the end of: (1) a fatigue-free day and (2) a fatigue-
inducing day. Participants reported increased mental fatigue and
effort after performing the n-back task, but only at the end of
the fatigue-inducing day. Moreover, reduced connectivity after the
fatigue-inducing day was observed in the frontal control network
that receives dopaminergic projections and is associated with exec-
utive abilities such as working memory. Other recent studies have
also found altered connectivity in the mesocorticolimbic pathway
in association with fatigue. Engström et al. (39) showed that MS
individuals who have high fatigue show reduced mesocorticol-
imbic connectivity compared to healthy adults during a complex
working memory task. Finke et al. (40) showed that high fatigue
scores in individuals with MS were negatively correlated with
resting-state mesocorticolimbic connectivity. At the same time,
pharmacological studies show a reduction in fatigue following a
dopamine agonist medication regimen [e.g., Ref. (41, 42)]. Con-
nectivity between the regions of the mesocorticolimbic pathway
has been shown to increase after dopamine agonist administration
(bromocriptine and methylphenidate) (43–45). Taken together,
these findings suggest that fatigue is associated with reduced con-
nectivity between the regions innervated with dopamine, possibly
due to reduced dopamine levels.
A potential difficulty in examining neural correlates of fatigue
during task-related functional neuroimaging studies is the assess-
ment of fatigue itself. In most of the clinical studies, fatigue is
assessed with a self-report questionnaire, such as the FSS (37)
or the Modified Fatigue Impact Scale (MFIS). These question-
naires provide non-specific,“global” data about the effect of “trait”
fatigue on physical, social, and other activities performed during
the previous weeks. However, functional neuroimaging studies are
performed during well-controlled cognitive tasks that are tied to
a specific time period and specific cognitive processes. A logical
solution for this potential problem is to assess fatigue during task
performance. Genova et al. (31) did precisely that: they asked par-
ticipants with MS to rate their fatigue on a scale from 0 (not at all
fatigued) to 100 (most fatigued), before and after a task-switching
paradigm, a task that heavily relies on executive processing, during
fMRI (46–48). These authors showed that activity in the striatum,a
primary input nucleus of the mesocorticolimbic pathway, is greater
in MS individuals who had higher on-task, or “state,” fatigue
compared to healthy individuals (31). Similarly, a recent study
reported impaired striatal functioning in individuals with CFS
(49). Collectively, these functional neuroimaging findings suggest
that individuals with fatigue have impaired functioning of the
mesocorticolimbic pathway, likely due to a dopamine imbalance
within the regions of this network.
SUPPORT FROM BEHAVIORAL PHARMACOLOGY
A large body of evidence in support of the dopamine imbalance
hypothesis is available from pharmacological studies. Several clin-
ical trials investigated the efficacy of psychostimulant medications
on fatigue in MS (50–53). Modafinil is a drug approved for treat-
ment of narcolepsy and has been shown effective in reducing
sleepiness (54). This medication might be the drug of choice for
fatigue treatment in MS, since fatigue often co-occurs with (or is
conflated with) sleepiness (55). However, studies that examined
modafinil efficacy for fatigue have been inconclusive due to small
sample sizes and methodological issues (open-label) (2, 56, 57).
Amantadine has also been used to treat fatigue in MS. Amantadine
is a dopamine agonists that leads to an increase in extracellu-
lar dopamine levels through promoting dopamine synthesis and
blocking reuptake. A recent randomized blinded trial with four
treatment groups (modafinil, amantadine, acetyl-l-carnitine, and
placebo) showed amantadine to be successful in reducing fatigue
(53). Of note is that Ledinek et al. (53) only included in their
study MS individuals who were undergoing interferon-beta treat-
ment (IFNβ). IFNβ is an immunomodulator that recently has been
shown to aid in catecholamine synthesis (58), with dopamine
being the most common catecholamine, as has been mentioned
above. While this evidence is promising, the majority of clinical
trials with amantadine are still underpowered and hence cannot
provide conclusive evidence (51).
Several recent clinical trials have examined the efficacy of
methylphenidate in treating fatigue. Methylphenidate, which has
been approved for treatment of attention deficit hyperactivity
disorder and narcolepsy, is a dopamine agonist that acts by inhibit-
ing presynaptic dopamine transporters leading to suppression
of dopamine reuptake (59, 60). That is, due to reuptake sup-
pression, more dopamine remains in the synapse. Recently, a
double-blind randomized placebo-controlled (DBRC) study uti-
lizing methylphenidate showed a decrease in fatigue in 36 Parkin-
son’s patients (61). A DBRC trial with 60 CFS patients also showed
that 20 mg of methylphenidate over 4 weeks is effective in reduc-
ing fatigue (41). Roth et al. (62) evaluated the effectiveness of
a 30 mg methylphenidate dose on fatigue in 36 cancer patients
in a DBRC trial, resulting in decreased fatigue after 6 weeks of
treatment (62). While clinical trials with methylphenidate on MS
fatigue are ongoing, the above findings support the dopamine
imbalance hypothesis and suggest that restoring dopamine lev-
els by means of dopaminergic medication results in fatigue
reduction.
MODULATORY EFFECTS OF DOPAMINE
Unlike the two major neurotransmitters, glutamate and gamma
aminobutyric acid, which have excitatory and inhibitory prop-
erties, respectively, dopamine is a neuromodulator. Studies in
animals and humans show that the influence of dopamine on cog-
nition follows an inverted “U” shape function (13, 25), with too
much or too little dopamine administration leading to impaired
cognitive performance. Fatigue might be subject to a similar mech-
anism. In the case of working memory, Gibbs and D’Esposito (63)
found that healthy participants who were given a dopamine ago-
nist (i.e., bromocriptine) showed an increase in working memory
capacity (63). Harel et al. (64) showed a similar effect in indi-
viduals with MS. The authors conducted a DBRC study with 26
MS patients. Patients were classified as working memory impaired
according to baseline performance on a complex task that involves
working memory, processing speed, and attention. Compared to
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the placebo control group, follow-up task performance in the
treatment group significantly improved after a single dose of
methylphenidate (10 mg) taken 1 h before task follow-up (64).
According to the dopamine imbalance hypothesis, administration
of a dopamine agonist, such as the methylphenidate, should have
lead to an increase in dopamine levels in the brain and a nega-
tive correlation between fatigue and performance; unfortunately,
Harel et al. (64) did not report fatigue measures such as the FSS
and the MFIS, or on-task fatigue.
Neuroimaging studies on working memory show that per-
formance improvement in individuals with low working mem-
ory capacity is accompanied by increased connectivity between
mesocorticolimbic structures increases after dopamine agonist
administration (43). Vytlacil et al. (65) also showed a correlation
between increased connectivity of the striatum and the midbrain
nuclei (VTA and SN) and working memory performance after
bromocriptine administration in individuals with low working
memory capacity; an opposite pattern of results was observed in
individuals with high working memory capacity. Similarly to what
has been observed in the working memory literature, fatigue has
been shown to be associated with reduced connectivity between
mesocorticolimbic structures (39, 40). However, the effect of
dopamine on mesocorticolimbic activation and connectivity in
individuals with fatigue has not yet been investigated.
According to the gating hypothesis, dopamine might modu-
late cognition due to its interaction with other neurotransmitters
in the PFC. When there is too much dopamine, the “gate” for
excitatory inputs from glutamate neurons to post-synaptic PFC
cells shuts down, while too little dopamine allows interference
between different inputs (13,19,25). Similar to the gating hypothe-
sis relating dopamine levels to cognition, the dopamine imbalance
hypothesis proposes that fatigue might occur when there is too
much or too little dopamine. Several studies show that while
fatigue decreases with dopaminergic medication, the effect might
be dose-dependent. Johansson et al. (42) observed a decrease in
fatigue while participants were on a low dose of methylphenidate
(5 mg), with an even greater decrease in fatigue observed when
participants were on a higher dose of methylphenidate (20 mg).
Similar results were obtained in hospice patients (66). Advanced
cancer patients who reported high baseline fatigue, had greater
fatigue reduction after 20 mg of methylphenidate (67, 68). Another
DBRC trial with 109 human immunodeficiency virus partici-
pants showed methylphenidate titration to be effective in reducing
fatigue. However, while some patients took the maximum dose of
the medication to achieve fatigue reduction (up to 60 mg per day),
other patients were able to achieve fatigue reduction with a lower
dose (69).
Taken together, these studies highlight the modulatory effect of
dopamine on cognition and fatigue. However, there is no evidence
showing an increase in fatigue when there is too much dopamine
in the CNS. Therefore, it remains to be tested if and at what dose
dopamine medication ceases to be helpful in reducing fatigue.
Given that dopamine is a neuromodulator that has been shown to
have a variable effect on cognition (i.e., too low or too high levels
of dopamine do not improve cognitive functioning), it is likely
that it has a similar effect on fatigue. That is, fatigue might result
from too much or too little dopamine in the brain.
THE ROLE OF DOPAMINE IN THE IMMUNE SYSTEM
Based in large part on the evidence from the MS animal model,
experimental autoimmune encephalomyelitis (EAE), MS is con-
sidered to be an autoimmune disorder of the CNS. To a large
extent, the immune system depends on the functioning of the
leukocytes or white blood cells. T cells are a type of white blood
cell that produce an immune response, i.e., they are activated
when the body needs to fight an infection. In autoimmune dis-
eases, including MS, T cells proliferate and attack healthy cells
(18), passing though the blood–brain barrier into the CNS. It has
been shown that proliferating CD4+ cells (a type of T cells) express
the D3 receptor that contributes to the destruction of dopamine
neurons in the SN and generate interferon-γ, a compound that
proliferates inflammation and prevents dopamine synthesis (11,
18, 70, 71). This potentially can result in decreased dopamine lev-
els. Indeed, animal studies showed that CNS dopamine depletion
by means of administration of the neurotoxin that kills dopamine
cells in the SN leads to EAE exacerbation, while daily adminis-
tration of a dopamine agonist, bromocriptine that has an affinity
for D2 DRs (of which the striatum has a high concentration),
has been shown to have beneficial effects on EAE. Treatment with
bromocriptine has been shown to result in reduced severity and
duration of relapses in rats with acute EAE. It also leads to the
suppression of prolactin, a pituitary hormone that is inhibited by
dopamine synthesized in the hypothalamus (see above) (10, 11, 17,
72). Though highly speculative, this line of reasoning suggests that
fatigue might occur due to the dopamine imbalance that starts in
the immune system, subsequently affecting the CNS.
IFNβ is an immunomodulatory drug approved for treatment
in relapsing remitting MS. It is the first line of treatment and
has been shown to prevent relapses. There are two types of IFNβ:
IFNβ-1a and IFNβ-1b (73). Even though the precise mechanism of
action of the IFNβ is not completely understood, it is thought that
IFNβ prevents relapses and slows disability progression through
retarding inflammatory processes, such as T-cell proliferation and
passing of the CD4+ T cells through the blood–brain barrier. More
importantly, recent findings also show that IFNβ treatment leads
to increased production of dopamine (58, 73–75).
Given that IFNβ increases dopamine synthesis, while dopamin-
ergic medications help increase levels of dopamine in the brain, it
is possible that individuals with MS on the IFNβ treatment might
benefit more from the dopaminergic fatigue treatment or even
have lower levels of fatigue than individuals with MS on a dif-
ferent treatment. To our knowledge, there is only one study that
looked at fatigue in relapsing remitting MS with IFNβ treatment
(76). Melanson et al. (76) in a non-randomized open-label study
showed that fatigue decreases in patients on IFNβ treatment.
OTHER FATIGUE HYPOTHESES
SEROTONIN
In their seminal paper, Chaudhuri and Behan (9) called on
researchers to clarify the roles of dopamine and serotonin in
fatigue. Indeed, both neurotransmitters innervate the basal gan-
glia, with serotonergic neurons projecting to the basal ganglia
from the raphe nuclei (77–79). The serotonin hypothesis devel-
oped because fatigue is a symptom of depression that is often
treated with selective serotonin reuptake inhibitors. Serotonergic
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levels in the CNS are particularly relevant in sports medicine, as
exercise has been shown to increase serotonin levels in the brain,
leading to amotivation (80, 81).
A few studies in clinical populations provide evidence in sup-
port of the serotonin hypothesis, suggesting that increased levels of
serotonin might lead to fatigue (82–84). For example, Pavese and
colleagues used 18F-DOPA and 11C-N, N -dimethyl-2-(2-amino-
4-cyanophenylthio) benzylamine to investigate dopamine storage
capacity and serotonin transmission, respectively, in the brain of
on-medication PD patients with and without fatigue (85). This
PET imaging study specifically focused on the basal ganglia and
limbic structures. The region-of-interest analysis revealed signifi-
cant differences in serotonin transmission between PD patients
with and without fatigue. However, significant differences in
dopamine storage capacity between PD patients with and with-
out fatigue were revealed only through the voxel-based analysis.
Thus, the results of this study support the serotonin hypothesis and
suggest that serotonin transmission might play a more important
role than striatal dopamine capacity in PD-related fatigue. Unfor-
tunately, the study of Pavese et al. had a rather small sample size
(8–10 per group) rendering the results inconclusive.
Clearly, delineating the neurobiological processes underlying
such a complex phenomenon as fatigue will not be simple. It is
likely that the interaction of several neurotransmitters systems is
involved in fatigue. Given the large body of evidence showing the
mesocorticolimbic network and, in particular the basal ganglia
involvement in fatigue, it is difficult to negate the involvement of
serotonin neurons that also innervate the basal ganglia. However,
recent studies show that decreased functioning of serotonergic
receptors leads to increased functioning of dopaminergic neu-
rons and dopamine release [for review see Ref. (86)]. Therefore,
given the preponderance of evidence to date, it appears that the
dopamine imbalance hypothesis of fatigue has the most support.
INFLAMMATORY CYTOKINES
Recently, it has been suggested that inflammatory cytokines, com-
pounds released by the cells of the immune system during inflam-
mation, might be the cause of fatigue. The cytokine hypothesis
developed based on the observation that fatigue co-occurs in
individuals who have inflammatory biomarkers, such as tumor
necrosis factor-α, interleukin-1, interleukin-6, and interferon-γ
(8, 87–89).
A large body of evidence in support of the cytokine hypoth-
esis comes from animal literature (8, 89). Indeed, animal studies
show that after administration of inflammatory cytokines in the
CNS, animals are less willing to exert effort in order to obtain
a reward. Nunes et al. (90) showed that administration of the
inflammatory cytokine interleukin-1β reduced effortful behavior
in rats (decreased amount of lever presses). However, it is impor-
tant to point out that effortful behavior is dopamine-dependent.
Lesioning a region of the fronto-striatal network or dopamine
depletion from fronto-striatal regions results in a cessation of
effortful behavior (23, 91, 92). Thus, it is possible that the effect
of cytokines on dopamine levels leads to fatigue, with dopamine
levels being the culprit in generating fatigue and not the cytokines
per se. Indeed, a recent study showed that methamphetamine,
a psychostimulant that affects dopamine and, to a lesser extent,
serotonin neurons, reduces frontocortical inflammatory cytokine
levels (93), while other studies show that inflammatory cytokines
have an effect on striatal functioning and dopamine release (87).
Thus, such data may support the dopamine imbalance hypothesis,
suggesting that the presence of inflammatory cytokines leads to
dopamine imbalance.
SUMMARY AND CONCLUSION
In this review, we propose that fatigue arises due to an imbalance
of dopamine, a modulatory neurotransmitter, in the CNS and the
immune system. Based on the evidence cited above and building
upon a previous framework on fatigue (9), we propose that fatigue
depends on the base levels of dopamine in the CNS. Neuroimaging
studies in clinical populations with fatigue repeatedly show struc-
tural and functional impairments in regions heavily innervated
by dopaminergic neurons, namely the striatum and the PFC (See
Supplementary Table 1 for the list of studies). While these brain
structures underlie a wide range of processes, converging evidence
suggests that an imbalance in dopamine plays a key role in fatigue.
Indeed, dopaminergic medication that increases dopamine lev-
els in the brain has been shown to increase the functioning and
connectivity between these regions in healthy individuals and to
decrease fatigue in clinical populations (See Supplementary Table 2
for the list of studies). Thus, the dopamine imbalance hypothesis
provides a unifying framework for the study of fatigue.
Given this framework, future research should be geared toward
testing specific aspects of the hypothesis. While studies in cog-
nition show that dopamine has a modulatory influence on cog-
nitive performance, clinical trials in fatigue so far only show
that dopaminergic medication decreases fatigue. Since fatigue and
cognitive functions such as working memory and attention rely
on a similar neural network, it is likely that dopamine has a
modulatory effect on fatigue as well. Future neuroimaging and
pharmacological research is needed to directly test whether this is
the case. Thus, an important question is, does fatigue increase as
dopamine levels increase above optimal levels? Another question
that should be investigated is whether dopamine agonist adminis-
tration decreases on-task or “state” fatigue in conjunction with
performance improvement. This will help in linking objective
measures of performance, which have been shown to be affected by
dopamine, with subjective on-task fatigue ratings. Pharmacologi-
cal studies should evaluate the effect of a dopaminergic medication
not only in comparison to a placebo but also in comparison
with non-dopaminergic medications, to show whether fatigue is
differentially affected by a dopaminergic medication versus, for
example, serotonergic medication.
Neuroimaging studies should focus on manipulating mesocor-
ticolimbic network activity in controlled experimental settings.
This would allow researchers to observe network functioning
in fatigued individuals and to answer specific questions about
the time course of network activation in a controlled environ-
ment. Investigating the time course of network activation during
task performance would reveal whether it correlates with on-task
fatigue. It is also worth looking at whether the increased con-
nectivity observed after dopamine medication, which has been
shown to lead to an increase in working memory performance, is
associated with fatigue reduction. Answering these questions will
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provide valuable evidence about the underlying mechanisms of
fatigue, and will ultimately allow us to develop targeted treatments
for fatigue.
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